Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring

Neuro Oncol. 2019 Dec 17;21(12):1610-1611. doi: 10.1093/neuonc/noz157.

Affiliations

¹ Radiation Oncology, Department of Medicine and Oncology, University Hospital, Pisa, Italy.
² Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
³ Department of Neuro-Oncology, University of Turin and City of Health and Science University Hospital, Turin, Italy.

No abstract available

Keywords: RAF; brain tumors; circulating free DNA; dabrafenib; exosome-derived cancer mRNA.

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Antineoplastic Agents / therapeutic use
Brain Neoplasms / blood
Brain Neoplasms / drug therapy*
Brain Neoplasms / genetics
Brain Neoplasms / pathology
Exosomes / genetics*
Female
Ganglioglioma / blood
Ganglioglioma / drug therapy*
Ganglioglioma / genetics
Ganglioglioma / pathology
Humans
Imidazoles / therapeutic use*
Mutation*
Oximes / therapeutic use*
Prognosis
Proto-Oncogene Proteins B-raf / genetics*
RNA, Neoplasm / blood*
RNA, Neoplasm / genetics

Substances

Antineoplastic Agents
Imidazoles
Oximes
RNA, Neoplasm
BRAF protein, human
Proto-Oncogene Proteins B-raf
dabrafenib